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Abstract
The 54 kDa subunit of the signal recognition particle (SRP54)
binds to the signal sequences of nascent secretory and
membrane proteins and it contributes to the targeting of these
precursors to the membrane of the endoplasmic reticulum (ER).
At the ER membrane, the binding of the signal recognition
particle (SRP) to its receptor triggers the release of SRP54 from
its bound signal sequence and the nascent polypeptide is
transferred to the Sec61 translocon for insertion into, or
translocation across, the ER membrane. In the current article,
we have characterized the specificity of anti-SRP54
autoantibodies, which are highly characteristic of polymyositis
patients, and investigated the effect of these autoantibodies on
the SRP function in vitro. We found that the anti-SRP54
autoantibodies had a pronounced and specific inhibitory effect
upon the translocation of the secretory protein preprolactin
when analysed using a cell-free system. Our mapping studies
showed that the anti-SRP54 autoantibodies bind to the amino-
terminal SRP54 N-domain and to the central SRP54 G-domain,
but do not bind to the carboxy-terminal M-domain that is known
to bind ER signal sequences. Nevertheless, anti-SRP54
autoantibodies interfere with signal-sequence binding to
SRP54, most probably by steric hindrance. When the effect of
anti-SRP autoantibodies on protein targeting the ER membrane
was further investigated, we found that the autoantibodies
prevent the SRP receptor-mediated release of ER signal
sequences from the SRP54 subunit. This observation supports
a model where the binding of the homologous GTPase domains
of SRP54 and the α-subunit of the SRP receptor to each other
regulates the release of ER signal sequences from the SRP54
M-domain.
Introduction
Both secretory and membrane proteins destined for entry into
the eukaryotic secretory pathway carry hydrophobic signal
sequences that direct them to the endoplasmic reticulum (ER).
The signal sequence is often located towards the amino termi-
nus of the protein, and in the case of presecretory proteins it
is proteolytically removed after targeting is completed [1].
These ER targeting signals are recognized and bound by a
small ribonucleoprotein complex, the signal recognition parti-
cle (SRP), as soon as they emerge from the ribosome during
protein synthesis [2-4]. This co-translational binding of SRP
causes an arrest or retardation of translation that is relieved
upon the interaction of the nascent chain/ribosome/SRP com-
plex with the SRP receptor complex located in the ER mem-
brane [3]. The binding of SRP to the SRP receptor allows the
release of the signal sequence from SRP in a process that is
dependent upon GTP binding and hydrolysis [3] and that also
requires the presence of the Sec61 translocon [5]. Translation
of the targeted nascent chain resumes and the free SRP can
enter a new cycle of targeting, while the signal sequence
inserts into the ER translocon and is cleaved on the luminal
side of the membrane by signal peptidase when a suitable site
is available [6]
ER = endoplasmic reticulum; Fab = antigen binding antibody fragment; IMC-CAT = a chimera of the invariant chain of MHC class II complex, multiple 
colony-stimulating factor and chloroamphenicol transferase; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; PL = prolactin; 
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Mammalian SRP consists of a 7S RNA and six proteins of
molecular weight 9 kDa, 14 kDa, 19 kDa, 54 kDa, 68 kDa and
72 kDa [3]. The SRP 9 kDa and 14 kDa proteins form a het-
erodimer that is involved in the SRP-mediated translation
arrest or retardation [3,7], while the SRP 19 kDa protein facil-
itates the binding of the 54 kDa subunit of the signal recogni-
tion particle (SRP54) to the 7S RNA [3,4]. The SRP54 subunit
binds to ER signal sequences via its methionine-rich carboxy-
terminal region (M-domain) and interacts with the SRP recep-
tor complex via its central GTP binding domain [3,4]. This lat-
ter interaction means that the targeting of nascent
polypeptides to the ER membrane is regulated by three
GTPases; that is, by SRP54 and both the α-subunit and β-
subunit of the SRP receptor [8,9].
Human autoantibodies often recognize epitopes that are con-
served during evolution and are essential for the function of the
autoantigen [10,11]. Previous studies have shown that human
autoantibodies against SRP immunoprecipitate the 7S RNA
and all the SRP protein subunits from HeLa cell extracts, but
recognize predominantly the SRP54 subunit on immunoblots
[12-14]. Anti-SRP autoantibodies occur almost exclusively in
patients with polymyositis, a syndrome characterized by
chronic muscle inflammation of unknown cause [12-14], and
they seem to define a distinct phenotypic, genetic and epide-
miologic subgroup of myositis patients [15,16]. In an attempt
to better characterize anti-SRP54 autoantibodies, we have
identified SRP54 epitopes of the anti-SRP autoantibodies
present in sera from polymyositis patients and investigated the
effects of these autoantibodies on SRP functions in vitro.
Materials and methods
Materials
The T7 RNA polymerase and restriction enzymes were
obtained from Roche Diagnostics GmbH (Mannheim, Ger-
many). 35S-Methionine was obtained from Amersham Buchler
GmbH (Braunschweig, Germany). Cycloheximide, 7-methyl-
guanosine 5'-monophosphate and puromycin were supplied
by Sigma Chemical Co. (St Louis, MO, USA). 4-(3-Trifluor-
omethyldiazarino)benzoic acid was a gift from Dr Josef Brun-
ner of the Swiss Federal Institute of Technology (Zürich,
Switzerland).
Antibodies
Rabbit antibodies against peptides or protein fragments
derived from SRP54 (831, 901, 903, 907, 908, 981, 982)
have been described previously [17]. Sera containing anti-
SRP autoantibodies used in this study were obtained from
patients with polymyositis and are a subset of those previously
described [15].
Affinity purification of human anti-SRP autoantibodies
The overexpression and purification of a fragment correspond-
ing to SRP54 amino acids 1–166 has been described previ-
ously [17]. A 1.8 mg sample of the purified fragment was
coupled to Affigel-10 resin (BioRad, Munich, Germany)
according to the instructions of the manufacturer. Briefly, 1 ml
antiserum 19-1 or antiserum 25-1 diluted 1:3 in PBS was
incubated overnight with the affinity matrix at 4°C. Unbound
material was recovered, and the matrix was washed with 40
volumes of PBS and eluted with 100 mM glycine-HCl, pH 2.5,
at 10 ml/hour. The peak fractions were pooled, dialysed
against 20 mM Hepes-KOH, pH 7.9, 250 mM potassium ace-
tate and were concentrated by centrifugation through Centri-
con-10 filter units (Amicon, Witten, Gemany) to 1 mg/ml final
protein concentration. The yield was about 250 µg/ml serum.
The unbound fraction was also dialysed and the volume was
reduced to 1 ml.
Preparation of Fab fragments
Fractions enriched for IgG were prepared from the human sera
by batch adsorption to DE52-Cellulose (Whatman, Dassel,
Germany). One millilitre of serum was incubated with 2.5 ml
DE52 equilibrated in 10 mM potassium phosphate, pH 7.8, for
2 hours at 4°C. Under these conditions, serum proteins with
the exception of IgG bound to DE52. The unbound fraction
contained approximately 95% pure IgG with transferrin as the
major contaminant. The yield was 4 mg IgG/ml serum. Fab
fragments were prepared from the unbound fraction by stand-
ard methods [18]. IgG and Fab fractions were dialysed into 20
mM Hepes-KOH, pH 7.9, 250 mM potassium acetate.
SRP54 constructs
The canine SRP54 and its truncated derivatives used to deter-
mine the anti-SRP autoantibody epitopes have been
described previously [17]. Plasmids containing the coding
regions for the SRP54 N-domain (SRP54N domain) and
SRP54 G-domain (SRP54G domain) were constructed by
PCR. The initiating ATG for SRP54N was changed to an NcoI
site and a stop codon was introduced at amino acid position
97. For SRP54G, amino acid 99 was changed to an initiating
ATG, its surroundings changed to an NcoI site and a stop
codon introduced in place of the codon for residue 295. The
PCR products were gel-purified and subcloned into pET-8c
[19].
In vitro transcription and translation of SRP54 and its 
derivatives
Linearized DNA was transcribed in vitro and translated in the
wheatgerm cell-free system for 60 minutes at 25°C [17].
Digestion of in vitro translated SRP54 with V8 (endoprotein-
ase Glu-C; Roche Diagnostics, Mannheim, Germany) was as
previously described [17].
Immunoprecipitations
For immunoprecipitations under 'native' conditions, 3–10 µl in
vitro translated material was diluted into 100 µl of 50 mM Tris-
HCl, pH 7.5, 1% Nonidet-P40, 150 mM NaCl, 2 mM ethylen-
ediamine tetraacetic acid, 20 µg/ml phenylmethylsulphonylflu-
oride. For denaturing conditions, samples in the same bufferAvailable online http://arthritis-research.com/content/8/2/R39
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plus 0.5% SDS were incubated at 95°C for five minutes and
were subsequently diluted 1:10 in buffer without SDS. Sam-
ples were precipitated with 1 µl serum or with 1 µg IgG or Fab.
In vitro translation and translocation of preprolactin
pSPBP4 contains the coding region for preprolactin (PPL)
[20] and was a gift from Peter Walter (University of California,
San Francisco, CA, USA). For translocation assays, full-length
PPL was synthesized as a 35S-methionine-labelled precursor
using a wheatgerm cell-free translation system supplemented
with 0.06 OD280 units of salt-washed dog pancreas rough
microsomes [21] and 20 nM canine SRP [22] for 1 hour at
25°C. One aliquot of the translocation reaction was analysed
directly by SDS-PAGE, a further aliquot was digested with 0.3
mg/ml proteinase K (Boehringer Mannheim, Mannheim, Ger-
many) for 10 minutes at 25°C and a third aliquot was treated
with proteinase K in the presence of 0.5% Nonidet-P40
(Sigma). The proteinase K was quenched by precipitation with
Figure 1
Human sera containing autoantibodies directed against SRP inhibit protein translocation into the ER in vitro Human sera containing autoantibodies directed against SRP inhibit protein translocation into the ER in vitro. The secretory precursor prepro-
lactin (PPL) was synthesized as a 35S-radiolabelled protein using a cell-free system supplemented with signal recognition particle (SRP)-depleted 
endoplasmic reticulum (ER) membranes and purified SRP that had been preincubated with either buffer (lanes 1 and 2) or with no additions (lanes 
3 and 4) to establish normal levels of prolactin (PL) translocation into ER-derived microsomes. The specificity of protein translocation was controlled 
for by performing experiments lacking exogenous SRP (lanes 5 and 6) or lacking salt-washed rough microsomal membranes (RM) (lanes 7 and 8). 
The complete translocation of signal-sequence-processed PL into the lumen of the ER microsomes was confirmed by showing resistance to diges-
tion by proteinase K (cf. - and + PK). To investigate the ability of distinct autoantibodies to block function, SRP was preincubated with various anti-
SRP-positive sera (S), IgG (I) or Fab (F) fractions prior to protein synthesis. TL, human control serum from a healthy individual, while 19-1, 17-1, 4-2 
and 25-1 are human sera containing anti-SRP autoantibodies from polymyositis patients. Serum 5–15 is from a polymyositis patient without detect-
able myositis autoantibodies, and serum 1–24 is from a polymyositis patient with autoantibodies directed against histidyl-tRNA synthetase. PPL, 
unprocessed (signal-sequence containing) preprolactin that has not been translocated into the ER microsomes. PL, fully translocated, signal-cleaved 
prolactin located inside ER microsomes. Samples were analysed by SDS-PAGE on 10–15% gels and by fluorography.Arthritis Research & Therapy    Vol 8 No 2    Römisch et al.
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10% trichloroacetic acid (final concentration) at 4°C for 30
minutes. To assay the effect of autoantibodies on SRP func-
tion, 3 µl of 250 nM SRP were incubated with 1 µl patient
serum or 1 µg IgG or Fab in 20 mM Hepes-KOH, pH 7.9, 250
mM potassium acetate at 25°C for 30 minutes. Then 2 µl of
this mixture were used for the in vitro translation/translocation
of PPL (25 µl final volume).
Photo-crosslinking assays
Ribosome bound fragments of the secretory protein PPL, an
artificial integral membrane protein derived from the N-termi-
nus of the invariant chain of the MHC class II complex, and the
transmembrane domain of multiple colony-stimulating factor
and chloroamphenicol transferase (IMC-CAT) were used to
assay the signal-sequence binding and ER targeting functions
of SRP [23,24]. In this study, an 86-residue N-terminal region
of PPL (PPL86) and a 103-residue N-terminal region of IMC-
CAT (IMC-CAT103) were synthesized in vitro as 35S-methio-
nine-labelled polypeptides as previously described [24].
Translation was carried out in a wheatgerm cell-free translation
system supplemented with 3.75 pmol ε-4-(3-trifluoromethyldi-
azarino)benzoyl-lysine tRNA per 25 µl reaction to incorporate
photo-activatable crosslinking probes into the nascent
polypeptides [24].
In order to assay for the effect of the autoantibodies on the sig-
nal-sequence binding ability of SRP, ribosome-arrested PPL86
complexes were synthesized in the absence of exogenous
SRP [25]. Canine SRP (0.5 pmol) was incubated with 2 µl
serum, IgG, Fab fragments, affinity-purified antibodies or
supernatant from affinity purification for 15 minutes at 25°C,
and this mixture was added to 30 µl PPL86 translation mixture
and incubated for a further five minutes at 25°C. The reaction
mixture was cooled to 0°C and was subsequently UV irradi-
ated as described elsewhere [25]. After irradiation the
crosslinked products were precipitated with trichloroacetic
acid and were analysed by SDS-PAGE.
To determine the effect of the autoantibodies on targeting to
the ER membrane, the IMC-CAT103 polypeptide was synthe-
sized in the presence of SRP to give a stable ribosome/nas-
cent chain/SRP complex [24]. Two microlitres of serum, IgG,
Fab fragments, affinity-purified antibodies or supernatant from
affinity purification were added to 30 µl aliquots of the transla-
tion mixture. The samples were incubated for 15 minutes at
25°C and then 0.1 OD280 units of salt-washed rough micro-
somes were added to each. Samples were incubated for 5
minutes at 25°C, cooled to 0°C and UV irradiated as already
described. After irradiation, the membranes were separated
from the cytosolic fraction by centrifugation through a high-salt
sucrose cushion. Thirty-microlitre samples were layered over a
150 µl cushion of 0.25 M sucrose, 50 mM Hepes-KOH, pH
7.5, 0.5 M KCl, 5 mM MgCl2 and the membranes were recov-
ered by centrifugation in a Beckmann airfuge [24]. The super-
natant was removed and precipitated with trichloroacetic acid
prior to analysis by SDS-PAGE. The membrane pellet was sol-
ubilized in sample buffer and analysed by SDS-PAGE. All sam-
ples were resolved on 10–15% SDS polyacrylamide gradient
gels and were subjected to fluorography prior to analysis.
Results
Human anti-SRP autoantibodies inhibit SRP-dependent 
protein translocation into the ER
SRP binds to ribosomes in such a way that SRP54 scans the
emerging nascent chains for the presence of a signal
sequence [2,26]. Once a signal sequence has been bound,
further elongation is retarded until contact is made between
SRP54 and the SRP receptor complex in the ER membrane.
In order to better characterize functionally important regions of
SRP54 in situ, we tested the effects of various sera containing
antibodies specific for the SRP54 protein upon co-transla-
tional SRP-dependent targeting to the ER membrane.
In the first instance, we investigated the effect of these sera on
the translocation of the secretory protein PPL into ER-derived
microsomes using a cell-free translation system. PPL was syn-
thesized in a wheatgerm system supplemented with salt-
washed canine rough microsomes and SRP. Under standard
conditions this leads to a significant level of protein transloca-
tion into the ER-derived microsomes, as evidenced by the
appearance of prolactin (PL) from which the signal sequence
had been cleaved (Figure 1, lanes 1 and 3). Signal-sequence
cleavage occurs in the ER lumen, suggesting that the proc-
essed material had been translocated into the microsomal
membranes. This was confirmed by establishing that the trans-
located PL chains were protected from digestion by exoge-
nously added proteinase K, and hence were enclosed inside
the microsomal membranes (Figure 1, lanes 2 and 4). In con-
trast, any remaining PPL from which the signal sequence had
not been cleaved was digested by proteinase K treatment
since it had not been translocated across the microsomal
membranes (Figure 1, lanes 2 and 4).
The role of canine SRP in mediating PPL translocation in this
cell-free system was confirmed by showing that no signal-
sequence-processed or protease-protected PL chains were
obtained when exogenous SRP was absent from the reaction
mixture (Figure 1, lanes 5 and 6). Hence, the salt-washing had
effectively removed all membrane-associated SRP from the
microsomal membrane preparation [27]. Likewise, no PL
chains were detected in the absence of added microsomal
membranes (Figure 1, lanes 7 and 8).
In order to investigate the ability of anti-SRP54 antibodies to
block SRP function, canine SRP was preincubated with vari-
ous sera containing different anti-SRP autoantibodies prior to
carrying out identical translocation assays using ER-derived
microsomes. While the autoantisera clearly recognize human
SRP54, it has been established that the amino acid
sequences of the human and canine SRP54 subunits are iden-Available online http://arthritis-research.com/content/8/2/R39
Page 5 of 13
(page number not for citation purposes)
Figure 2
Characterization of the regions of SRP54 recognized by the human autoantibodies Characterization of the regions of SRP54 recognized by the human autoantibodies. (a) Summary of the immunoprecipitation of SRP54 and its 
fragments by the autoantibodies. A restriction map of the plasmid encoding SRP54 is shown at the top (cf [17]): S, SphI; H, HindIII; E, EcoRI; Ba, 
BamHI; Bg, BglII. The complete SRP54 protein and truncated derivatives are outlined underneath. The names of the polypeptides are shown on the 
left, and their size in amino acids and the immunoreactivity with the patient autoantibodies is indicated on the right. (b) Immunoprecipitation of 
SRP54 and its separate domains by sera 19-1 and 25-1 autoantibodies affinity-purified on an amino-terminal SRP54 fragment (amino acids 1–166). 
SRP54, SRP54N, SRP54G and SRP54M domains were synthesized as 35S-radiolabelled polypeptides in vitro and an aliquot loaded directly onto 
the gel (Tot). Other aliquots were immunoprecipitated under native conditions with 1 µl serum (Ser), with 1 µl flow-through from the affinity column 
(Sup) or with 1 µg affinity-purified IgG (Aff). Samples were analysed by SDS-PAGE on 10–15% gels and by fluorography. The estimated molecular 
masses of the proteins were 54 kDa (SRP54), 23 kDa (SRP54G domain), 21 kDa (SRP54M domain) and 12 kDa (SRP54N domain).Arthritis Research & Therapy    Vol 8 No 2    Römisch et al.
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tical [28]. Hence, the autoantisera should recognize the
canine SRP54 subunit equally well. A number of antisera have
been raised against synthetic peptides and recombinant frag-
ments SRP54 in animals [17]; however, none of these had any
effect upon PPL translocation in the assay outlined (data not
shown). In contrast, the preincubation of SRP with human sera
containing autoantibodies against SRP proteins from a
number of polymyositis patients (19-1, 17-1, 4-2 and 25-1)
completely abolished the translocation of the secretory protein
precursor PPL into ER-derived microsomes (Figure 1, cf. lanes
15, 16, 21, 22, 27, 28, 33 and 34). No processing of PPL to
PL by the luminal signal peptidase was therefore observed
(Figure 1, lanes 15, 21, 27 and 33) and no protease-protected
PL chains were seen after treatment with proteinase K (Figure
1, lanes 16, 22, 28 and 34).
That these effects were due to anti-SRP autoantibodies rather
than other serum components was supported by the finding
that preincubation with sera from a normal human control or
from polymyositis patients containing either no detectable
myositis autoantibodies (serum 5–15) or with anti-Jo-1
autoantibodies directed against histidyl-tRNA synthetase
(serum 1–24) had little or no effect on PPL translocation (Fig-
ure 1, lanes 9, 39 and 45), and the finding that protease-pro-
tected PL was observed in all cases (Figure 1, lanes 10, 40
and 46). The specificity of these effects was underlined by the
observation that both purified IgG fractions and monovalent
Fab fragments gave almost identical results to those seen with
the crude sera from which they were derived.
Characterization and affinity purification of anti-SRP 
autoantibodies
As judged by immunoblotting, the anti-SRP autoantibodies
from a number of patients react with SRP54 and the SRP 68
kDa and 72 kDa proteins – only serum 17-1 appeared to rec-
ognize solely SRP54 [14]. Immunoprecipitation from a mixture
of in vitro translated SRP54 and the SRP 68 kDa and 72 kDa
proteins suggested that the major fraction of each of the
autoantibodies is directed against SRP54 (data not shown). In
order to characterize the region of SRP54 recognized by the
various autoantibodies, immunoprecipitations of a series of in
vitro  synthesized SRP54 fragments were performed. The
results were identical with or without prior SDS denaturation,
and are presented schematically in Figure 2a. On the basis of
this analysis, we conclude that sera 4-2 and 17-1 recognize a
region within the carboxy-terminal 130 amino acids of the
SRP54G domain, while sera 19-1 and 25-1 recognize a
region within the SRP54N domain. The epitope for 19-1
seems to be located more towards the N-terminus of this
region than that of 25-1, since serum 19-1 precipitates the
HindIII and SphI derived fragments of SRP54 equally well
whereas serum 25-1 reacts less well with the shorter SphI
fragment (Figure 2a). It is worth noting that none of the patient
autoantibodies tested recognized the C-terminal SRP54 M-
domain (SRP54M domain) (Figure 2a).
In order to establish whether the inhibitory effect of the human
autoantibodies upon PPL translocation was a direct conse-
quence of their anti-SRP54 activity, and to investigate whether
antibodies recognizing different domains of SRP54 had differ-
ent effects upon SRP function, specific antibodies were affin-
ity-purified from sera 19-1 and 25-1. This was achieved using
a 166-residue long N-terminal fragment of SRP54 that is
equivalent to the N-domain plus a part of the G-domain (see
[17]; Figure 2a, BamHI derived fragment). The unbound frac-
tion of the sera was also retained to establish whether it con-
tained any distinct SRP54 reactive antibodies as a result of
multiple activities being present in a single serum. Specificity
was determined by immunoprecipitation of in vitro synthesized
SRP54 fragments.
For both sera 19-1 and 25-1, the affinity-purified antibodies
and the unbound fraction immunoprecipitated full-length
SRP54 at a comparable level with the original sera (Figure 2b,
lanes 2–7). When the SRP54N domain was examined, how-
ever, only the original sera and the affinity-purified antibodies
reacted with this region (Figure 2b, lanes 9, 10, 12 and 13)
while the unbound serum-derived fractions did not (Figure 2b,
lanes 11 and 14). The affinity purification therefore specifically
recovered autoantibodies recognizing the SRP54N domain
while the unbound fraction was completely depleted of this
activity. The specificity of the affinity-purified autoantibodies
was further supported by the observation that neither prepara-
tion recognized the SRP54G domain (Figure 2b, lanes 17 and
20). The unbound material recovered from serum 19-1 did
immunoprecipitate the SRP54G domain (Figure 2b, lane 18),
while the equivalent fraction from serum 25-1 did not immuno-
precipitate (Figure 2b, lane 21). We conclude that serum 19-
1 contains at least two different antibody species, one recog-
nizing the SRP54N domain within its N-terminal 78 residues
(Figure 2a, SphI fragment and Figure 2b, SRP54N reactivity of
affinity-purified antibodies) and the second specific for a por-
tion of the SRP54G domain between residues 166 and 295
(Figure 2a, SRP54N+G and Figure 2b, SRP54G reactivity of
unbound fraction).
We next established whether the effect of the autoantisera
upon the SRP-dependent targeting reaction could be repro-
duced using purified autoantibodies. When the effect of the
affinity-purified autoantibodies was examined, both the sera
19-1 and 25-1 derived samples were shown to block PPL
translocation into rough microsomes as previously observed
with the original sera (Figure 3, lanes 1–4). We therefore con-
clude that autoantibodies specific for the SRP54N domain
can inhibit SRP function in an in vitro system. In both cases the
unbound fraction also blocked SRP function (Figure 3, lanes
5–8), however, indicating that other activities may contribute
to the effect of the original sera. In the case of 19-1, this may
be attributed to the second SRP54G domain-reactive compo-
nent of the serum we defined earlier. For serum 25-1, however,
the unbound fraction was depleted of any detectable SRP54NAvailable online http://arthritis-research.com/content/8/2/R39
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reactive antibodies (see Figure 2b, lane 14) and showed no
reaction with either SRP54G or SRP54M (Figure 2b, lanes 21
and 28).
One possibility was that serum 25-1 contained a second
SRP54-reactive autoantibody population that recognized an
epitope near the boundary of two of the SRP54 domains such
that this was absent when they were analysed in isolation (cf.
Figure 2b). To address this issue, SRP54 was treated with V8
protease to generate an intact SRP54N+G domain and a sep-
arate SRP54M domain [17]. The resulting products were then
analysed by immunoprecipitation, and in this case we found
that the SRP54N+G domain was efficiently recognized by the
unbound serum 25-1 derived fraction following affinity purifi-
cation (Figure 3b, lane 8). Thus, as is the case for serum 19-1,
we conclude that 25-1 contains at least two distinct autoanti-
body populations that recognize distinct regions within the
SRP54 protein.
Anti-SRP autoantibodies interfere with signal-sequence 
binding of SRP54
Having obtained clear evidence that autoantibodies recogniz-
ing SRP54 could interfere with the SRP-dependent targeting
process, we investigated the stage of the pathway at which
targeting was inhibited. The first step required for SRP-
dependent translocation of a nascent polypeptide chain
across the ER membrane is the binding of its signal sequence
to SRP54. The interaction between a signal sequence and
SRP54 can be directly assessed by crosslinking [29]. We
investigated the influence of preincubation of SRP with human
anti-SRP autoantibodies upon its ability to bind to the PPL sig-
nal sequence using a well-established photo-crosslinking
assay as a readout. When SRP54 is correctly bound to the
PPL signal sequence, a radiolabelled, UV-dependent, photo-
crosslinking product of 63 kDa is seen (Figure 4a, cf. lanes 1
and 2, PPL86/SRP54 indicated by white arrowhead; see also
[25]). We found that the IgG fractions from polymyositis
patients containing anti-SRP54 autoantibodies (sera 17-1,
19-1, 25-1, 4-2), but not from polymyositis patients without
myositis autoantibodies or with other specificities (sera 1–24,
5–15), significantly reduced the crosslinking of SRP54 to the
PPL signal sequence (Figure 4a, lanes 3–8, PPL86/SRP54,
white arrowheads). When the levels of adduct formation were
quantified, we discovered an approximately threefold reduc-
tion in crosslinking to SRP54 (Figure 4b). The crude sera and
Fab preparations from each of these samples gave similar
results (data not shown).
When the affinity-purified autoantibodies specific for the
SRP54N domain were analysed, it was striking that they had
no substantial effect upon the binding of SRP54 to the PPL
signal sequence (Figure 4a, lanes 10 and 11, PPL86/SRP54,
white arrowheads). In contrast, the unbound fractions derived
from these preparations gave a level of inhibition comparable
with the IgG fractions (Figure 4a, lanes 4, 5, 12 and 13, PPL86/
SRP54, white arrowheads; see Figure 4b for quantification).
Taken together, these data suggest that autoantibodies spe-
cific for the SRP54G domain (serum 19-1) and the SRP54N/
G boundary (serum 25-1) block SRP binding to the PPL signal
Figure 3
Distinct autoantibodies against the SRP54N and SRP54G domains  can both inhibit secretory protein translocation into the ER Distinct autoantibodies against the SRP54N and SRP54G domains 
can both inhibit secretory protein translocation into the ER. (a) The 
secretory protein preprolactin (PPL) was synthesized as a 35S-radiola-
belled precursor in vitro in the presence of salt-washed rough micro-
somes (RM) and signal recognition particle(SRP) that was 
preincubated with affinity-purified autoantibodies from sera 19-1 or 25-
1 on SRP54 amino acids 1–166 (Aff), with the flow-through fractions 
(Sup) or with buffer alone. SRP without preincubation (lanes 11 and 
12) and translations without added SRP (lanes 13 and 14) or RM 
(lanes 15 and 16) were used as positive and negative controls, respec-
tively. Samples were treated with proteinase K or not (+ or - PK) and 
were analysed by SDS-PAGE on 10–15% gels and by fluorography. 
(b) Serum 25-1 contains two distinct anti-SRP54 activities. SRP54 
was synthesized as a 35S-radiolabelled protein in vitro and either 
digested with V8 protease (+ V8) or incubated in the absence of pro-
tease (- V8) as described previously [17]. An aliquot of both digested 
and undigested material was loaded onto the gel directly (Tot). Both 
digested and undigested material were immunoprecipitated using 1 µl 
serum 25-1 (Ser), using 1 µl affinity-column flow-through (Sup) or using 
1 µg affinity-purified autoantibodies from serum 25-1 (Aff). Samples 
were analysed by SDS-PAGE on 10–15% gels and by fluorography.Arthritis Research & Therapy    Vol 8 No 2    Römisch et al.
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sequence in vitro. These data also suggest that any effect of
the affinity-purified antibodies specific for the SRP54N
domain upon SRP function (Figure 3a) must occur at a point
after signal-sequence binding has occurred.
Anti-SRP autoantibodies inhibit targeting to the ER 
membrane and the release of SRP54 from the signal 
sequence
Following the binding of SRP to a signal sequence present on
a nascent polypeptide, the next step during ER targeting is the
association of the ribosome/nascent chain/SRP complex with
the SRP receptor complex [3]. This interaction leads to the
release of the signal sequence from SRP54, allowing the
polypeptide to interact with the ER translocation machinery
[30]. In order to investigate the influence of the autoantibodies
on this targeting step, we used a well-characterized, ribosome-
associated, membrane protein fragment (IMC-CAT103) to gen-
erate stable ribosome/nascent chain/SRP complexes [24].
These complexes were then preincubated with the original
human sera, or the affinity-purified autoantibodies and their
corresponding unbound fractions, and the effect of this prein-
cubation on the targeting of the ribosome/nascent chain/SRP
complexes to the ER membrane was assessed. Following the
incubation of the pretreated ribosome/nascent chain/SRP
preparations with rough microsomes, the membrane fraction
was recovered by centrifugation. We noted that preincubation
of the ribosome/nascent chain/SRP complexes with sera con-
taining SRP autoantibodies significantly reduced the propor-
tion of nascent IMC-CAT103  chains recovered in the
membrane fraction, consistent with a blockade at some early
stage of the membrane insertion process (data not shown).
Following the isolation of the membrane fraction, the associa-
tion of the IMC-CAT signal sequence with SRP54 was
assayed by crosslinking as previously described for PPL (see
Figure 4a). In the presence of membranes, the release of the
Figure 4
Human autoantibodies against the SRP54G domain inhibit crosslinking of SRP54 to the PPL signal sequence Human autoantibodies against the SRP54G domain inhibit crosslinking of SRP54 to the PPL signal sequence. (a) Canine SRP was preincu-
bated with no additions (lane 9), with IgG fractions containing anti-SRP autoantibodies (lanes 3 to 8), with affinity-purified autoantibodies (Aff, lanes 
10 and 11) or with their accompanying unbound fractions (Sup, lanes 12 and 13), and subsequently incubated with a 35S-radiolabelled fragment of 
preprolactin (PPL) present in the form of a ribosome nascent chain complex (PPL86). The interaction of the SRP54 subunit with the signal sequence 
of PPL86 was determined by UV-induced crosslinking. A non-irradiated sample (lane 1) and a sample lacking exogenously added SRP (lane 2) are 
shown as controls. The ~63 kDa crosslinking product (PPL86/SRP54) resulting from the crosslinking of the 86-residue PPL fragment to the 54 kDa 
subunit of canine SRP is indicated by a white arrowhead. A faint ~61 kDa product is visible in some lanes, especially where the binding of the canine 
SRP is strongly inhibited. This smaller species represents crosslinking of the nascent chain to the endogenous wheatgerm SRP54 homologue, and 
this product is normally only observed in the absence of canine SRP [34]. The ~9 kDa PPL86 fragment is indicated, as are the locations of full-length 
preprolactin (**) resulting from incomplete linearization of the DNA template for transcription of PPL86, and a peptidyl-tRNA species (*) resulting from 
the incomplete hydrolysis of the PPL86-tRNA bond during sample preparation. (b) The intensity of the 63 kDa band in (a) was quantified by scanning 
with an LKB Ultroscan XL enhanced laser densitometer. The most intense band achieved with a control serum or blank in each set (for instance, 
lanes 3–8 and lanes 9–13) was set to 100%.Available online http://arthritis-research.com/content/8/2/R39
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signal sequence from SRP54 is usually very efficient and
results in an almost complete loss of the ~65 kDa IMC-
CAT103/SRP54 product (Figure 5, lane 7). The accompanying
appearance of a distinct ~48 kDa product (Figure 5, lane 7,
IMC-CAT103/Sec61α) reflects the transfer of the nascent
chain from SRP54 to the Sec61 translocon [31]. When the
two human sera lacking anti-SRP autoantibodies were ana-
lysed they gave similar results to the control and efficient
release of the nascent chain from SRP54, and transfer to the
Sec61 complex was seen (Figure 5, lanes 5 and 6). In con-
trast, for the samples incubated with sera containing anti-SRP
autoantibodies, the ER membrane-associated nascent chains
remained bound to SRP54 and no release to the Sec61 com-
plex was seen (Figure 5, lanes 1 to 4). Similar results were
seen with the IgG fractions and Fab fragments prepared from
these six human sera (data not shown).
When the two affinity-purified antibody preparations were ana-
lysed in the same assay, they were also found to completely
block the membrane-dependent release of SRP54 from the
nascent IMC-CAT chains and only crosslinking to SRP54 was
apparent (Figure 5, lanes 8 and 9). Likewise, the two accom-
panying unbound fractions resulting from the affinity purifica-
tion of SRP54N domain-specific autoantibodies also
Figure 5
Autoantibodies against SRP54N and SRP54G domains inhibit release of the signal sequence from SRP54 at the endoplasmic reticulum membrane Autoantibodies against SRP54N and SRP54G domains inhibit release of the signal sequence from SRP54 at the endoplasmic reticulum 
membrane. A 103-residue fragment of a model membrane protein derived from regions of the invariant chain of the MHC class II complex, multiple 
colony-stimulating factor and chloroamphenicol transferase (IMC-CAT103) was synthesized in vitro as a 35S-radiolabelled polypeptide in the pres-
ence of SRP and ε-4-(3-trifluoromethyldiazarino) benzoyl-lysine tRNA to yield a stable ribosome/nascent chain/signal recognition particle complex. 
Cycloheximide was added to prevent further chain elongation and the complex was incubated with sera (lanes 1–6), with no additions (lane 7), with 
affinity-purified antibodies (Aff, lanes 8 and 9) or with their corresponding unbound fractions (Sup, lanes 10 and 11). Following the addition of endo-
plasmic reticulum membranes and the activation of the crosslinking reaction by UV irradiation, membrane-targeted nascent chains were isolated by 
sedimentation through a high-salt/sucrose cushion and the resulting samples were analysed by SDS-PAGE on 10–15% gels and by fluorography. 
The locations of the IMC-CAT103 polypeptide (IMC-CAT103), of IMC-CAT103 crosslinked to SRP54 (IMC-CAT103/SRP54) and of IMC-CAT103 
crosslinked to Sec61α (IMC-CAT103/Sec61α) are indicated.Arthritis Research & Therapy    Vol 8 No 2    Römisch et al.
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completely blocked the release of SRP54 from the nascent
IMC-CAT chains (Figure 5, lanes 10 and 11). Affinity-purified
autoantibodies specific for the SRP54N region (Figure 5,
lanes 8 and 9) and sera containing autoantibodies recognizing
the SRP54G domain can therefore inhibit the SRP receptor-
mediated release of SRP from an ER signal sequence.
The SRP receptor shows both sequence and structural
homology to the N-domain and G-domain of SRP5 [32,33]. It
was therefore possible that the autoantibodies bound directly
to the SRP receptor and thereby interfered with the release of
SRP54 from signal sequences. We found no evidence for any
interaction of the anti-SRP autoantibodies with the SRP
receptor by immunoprecipitation or immunoblotting, however,
and the preincubation of ER membranes with autoantibodies
had no effect on protein targeting or translocation, confirming
the absence of any function-blocking effect on membrane
components (data not shown). We therefore conclude that the
inhibitory effect of the anti-SRP autoantibodies on protein tar-
geting is due to their direct interaction with SRP, and primarily
with SRP54.
Discussion
Human autoantibodies that react with SRP have been previ-
ously described and shown to immunoprecipitate the 7SL
SRP RNA component and to react strongly with SRP54 on
immunoblots [12-14]. Anti-SRP autoantibodies are part of a
family of myositis-specific antibodies that are directed primarily
against conserved conformational epitopes on cytoplasmic
components involved in protein synthesis [10]. A unique fea-
ture of a number of myositis-specific autoantibodies is that
they, in contrast to animal antisera raised to the same proteins,
Figure 6
Schematic showing the effect of subdomain-specific autoantibodies on SRP54 function Schematic showing the effect of subdomain-specific autoantibodies on SRP54 function. (a) Autoantibodies against the SRP54G domain 
inhibit signal-sequence binding. Two conformations for SRP54 have been proposed: one where the signal sequence (S) binding groove of the 
SRP54M domain is closed (i) and the second where it is open (ii). Autoantibodies directed to the G-domain of SRP54 may prevent the conforma-
tional change required to open the signal-sequence binding pocket (iii) [44]. (b) Autoantibodies against the SRP54N or SRP54G domain prevent 
signal-sequence release from SRP54 and membrane insertion. When SRP54 interacts with the SRP receptor (SR) at the endoplasmic reticulum 
(ER) membrane, the signal sequence is released from the M-domain and inserts into the Sec61p translocon in the ER membrane (i). In the presence 
of autoantibodies directed against the SRP54N or SRP54G domain, the signal sequence remains bound to SRP54 (ii and iii). Ribosomes have been 
omitted from the nascent chains for the sake of simplicity. The diagrammatic representation of the SRP54 subunit in this model is based on our cur-
rent understanding of its three-dimensional structure [9,44] rather than on the simple linear organization of the three domains presented in Figure 2a.Available online http://arthritis-research.com/content/8/2/R39
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have been found to inhibit the functions of their respective
autoantigens [11]. We therefore investigated the effects of
anti-SRP autoantibodies on SRP function in vitro.
Sera from polymyositis patients containing anti-SRP autoanti-
bodies specifically inhibited the in vitro translocation of the
secretory protein PPL into the ER. Both IgG fractions and Fab
fragments had the same effect, suggesting that a wide-ranging
steric inhibition was not occurring. We concluded that one or
more anti-SRP autoantibodies present in these sera could
block the ER targeting function of SRP. Since SRP54 plays a
pivotal role in this process [3,4], and since anti-SRP positive
sera were known to contain autoantibodies recognizing
SRP54 [15], we focused on the antiSRP54-specific reactivity
of these autoantisera.
We first mapped the region(s) of SRP54 that the anti-SRP
positive human sera recognized and found that all four of the
sera tested (4-2, 17-1, 19-1 and 25-1) contained autoantibod-
ies that recognized an epitope(s) located within the SRP54G
domain. Both sera 19-1 and 25-1 also contained a distinct
reactivity towards the SRP54N domain. The SRP54N and
SRP54G domains are primarily involved in binding to the SRP
receptor (cf. Figure 6b), although these regions may indirectly
influence signal-sequence binding [34-36]. None of the sera
recognized epitopes in the SRP54M domain, the region of the
protein that binds to ER targeting signals [3,4].
Autoantibodies specific for an N-terminal region of SRP54,
including the N-domain and part of the G-domain, were affin-
ity-purified from sera 19-1 and 25-1 and were analysed for
their effects upon SRP function. We found that both the affin-
ity-purified material, representing autoantibodies specific for
the SRP54N domain, and the unbound fraction, which
included the activity recognizing the SRP54G domain,
blocked PPL translocation in a cell-free system. Autoantibody
binding to both of these regions could therefore block SRP-
mediated targeting to the ER.
Protein translocation across the ER membrane requires sig-
nal-sequence binding to SRP54, followed by targeting of the
SRP/nascent secretory protein/ribosome complex to the ER
membrane [3]. We found that all of the anti-SRP autoantisera
interfered with the binding of SRP54 to the PPL signal
sequence when this process was examined directly by photo-
crosslinking [25]. While the affinity-purified antibodies specific
for the SRP54 N-terminal region had no effect, the unbound
antibodies recovered during the purification displayed a
strong inhibition of SRP54 binding. We conclude that the
binding of SRP54G domain-specific autoantibodies inhibits
the ability of SRP to bind to the signal sequence of PPL (Fig-
ure 6a, iii). We cannot, however, formally exclude the possibil-
ity that this unbound antibody fraction also contains activities
that inhibit the function of other SRP subunits, such as the
SRP 68 kDa and SRP 72 kDa proteins [37].
Having established that anti-SRP autoantibodies block signal-
sequence binding, we investigated their effect upon the SRP-
dependent targeting [38]. To study this process we used the
model membrane protein IMC-CAT, which contains a signal-
anchor sequence that binds to the SRP54 subunit and, upon
SRP receptor-mediated delivery to the ER membrane, is sub-
sequently transferred to the Sec61 translocon for membrane
integration [24,31] (Figure 6b, i). All four anti-SRP sera com-
pletely blocked the transfer of nascent IMC-CAT chains from
SRP54 to the Sec61 complex, and the affinity-purified,
SRP54N domain-specific antibodies displayed the same level
of inhibition as the crude sera. Thus, in contrast to the effects
upon signal-sequence binding, autoantibodies specific for
both the SRP54N and SRP54G domains can block SRP
receptor-mediated targeting to the ER membrane (Figure 6b,
ii and 6b, iii). This is entirely consistent with our current under-
standing of the pivotal role played by the SRP54N and
SRP54G domains in the interaction of SRP with the SRP
receptor [39,40] (Figure 6b, i). Whether the effect of the anti-
SRP autoantibodies is simply to prevent the authentic binding
of SRP54 and the SRP receptor, or whether their binding
compromises a specific function such as GTP hydrolysis,
remains to be established.
Conclusion
Autoantibodies have frequently been shown to inhibit the func-
tion of their target antigens; hence, anti-Sm autoantibodies
specifically inhibit mRNA splicing [41] while anti-PCNA
autoantibodies inhibit DNA replication [42]. This study pro-
vides an example of myositis autoantibodies that, unlike anti-
bodies raised in animals to the same protein, act to inhibit the
function of their target autoantigen [11]. A previous study of
myositis autoantibody inhibition of autoantigen function found
that all six of the anti-aminoacyl-tRNA synthetase antibodies
that were tested inhibited enzymatic activity [43].
The reasons for the clear functional differences between spon-
taneously arising human autoantibodies and animal antibodies
raised by immunization with the same protein remain unclear.
The findings that myositis autoantibodies arise months prior to
clinical disease onset, are antigen-driven and isotype-
restricted, have stable spectrotypes, bind to conformational
rather than linear epitopes and inhibit the function of their tar-
gets, however, all suggest inherent differences in how immune
systems respond to autoantigens versus injected antigens
[10,11]. One possibility is that human autoantibodies result
from interactions of immune-targeted autoantigens with spe-
cific environmental agents in the context of disease-associ-
ated immunogenetic alleles.
Whatever their origin, myositis autoantibodies continue to pro-
vide useful tools both for clinical diagnosis and prognosis, and
for dissecting the molecular function of their target autoanti-
gens, including the SRP.Arthritis Research & Therapy    Vol 8 No 2    Römisch et al.
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